Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JLUA | ISIN: US00302L1089 | Ticker-Symbol:
NASDAQ
23.01.25
21:38 Uhr
4,015 US-Dollar
0,000
0,00 %
1-Jahres-Chart
ABRDN GLOBAL PREMIER PROPERTIES FUND Chart 1 Jahr
5-Tage-Chart
ABRDN GLOBAL PREMIER PROPERTIES FUND 5-Tage-Chart
ACCESS Newswire
183 Leser
Artikel bewerten:
(1)

abrdn Global Premier Properties Fund Announces "At-the-Market" Equity Offering Program

Finanznachrichten News

PHILADELPHIA, PA / ACCESS Newswire / January 23, 2025 / abrdn Global Premier Properties Fund (NYSE:AWP) (the "Fund"), a closed-end fund, has announced that it filed with the U.S. Securities and Exchange Commission ("SEC") on January 23, 2025, a prospectus supplement to its registration statement under which it may offer and sell from time to time, in one or more at-the-market offerings, the Fund's common shares having an aggregate offering price of up to $27.5 million (the "ATM Program").

The Fund may not sell any common shares at a price below the current net asset value ("NAV") of such common shares, exclusive of any distributing commission or discount. There can be no guarantee that the Fund will engage in any sales or any particular level of sales of common shares, if shares are offered. It is anticipated that any proceeds raised would be used for investment purposes.

An investor should read the Fund's prospectus and prospectus supplement carefully before investing in the Fund. The Fund's shares may be offered directly to one or more purchasers, through agents designated from time to time by the Fund, or to or through underwriters or dealers. The prospectus supplement relating to the offering will identify any agents, underwriters or dealers involved in the sale of Fund shares, and will set forth any applicable purchase price, fee, commission or discount arrangement between us and our agents or underwriters, or among our underwriters, or the basis upon which such amount may be calculated. The Fund's shares may not be sold through agents, underwriters or dealers without delivery of a prospectus supplement describing the method and terms of the particular offering of Fund shares.

Investors may request these documents free of charge from the Fund's website at www.abrdnawp.com or obtain these documents on the SEC's website at www.sec.gov.

###

The information in this press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

There can be no assurance that the Fund will achieve its investment objectives. The NAV of the Fund will fluctuate with the value of the underlying securities. It is important to note that closed-end funds trade on their market value, not NAV, and closed-end funds often trade at a discount to their NAV. Past performance is not indicative of future performance. An investment in the Fund is subject to certain risks and other considerations.

The Fund is a diversified, closed-end management investment company. The Fund seeks high current income and capital appreciation. The price of the Fund's common shares is determined by a number of factors, many of which are beyond the control of the Fund.

The Fund is advised by abrdn Investments Limited and sub-advised by abrdn Inco. The Fund's common shares trade on the NYSE under the symbol "AWP."

In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, and abrdn ETFs Advisors LLC.

Investors should consider the Fund's investment objectives, risks, charges and expenses carefully before investing in the Fund. There is no assurance that the Fund will achieve its investment objective.

Closed-end funds are traded on the secondary market through one of the stock exchanges. The Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the NAV of the fund's portfolio.

abrdnawp.com

###

For More Information Contact:
abrdn Inc.
Investor Relations
800-522-5465
Investor.Relations@abrdn.com

SOURCE: abrdn Global Premier Properties Fund



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.